Prostate Cancer - Results from #640

Role of gut microbiota in the pathogenesis of castration-resistant prostate cancer: a comprehensive study using sequencing and animal models. July 8, 2024

AKT Inhibition Sensitizes to Polo-Like Kinase 1 Inhibitor Onvansertib in Prostate Cancer. July 8, 2024

Intensifying Salvage Therapy in Prostate-specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy with Apalutamide, Salvage Radiation, and Docetaxel: The Phase 2 STARTAR Trial. July 8, 2024

PSA Stratification for Predicting Advanced Prostate Cancer Events in Men Approaching Age-Limits for Recommended Screening. July 8, 2024

Single-cell analysis of treatment-resistant prostate cancer: Implications of cell state changes for cell surface antigen-targeted therapies. July 8, 2024

Impact of a rash management guide in patients receiving apalutamide for high-risk localized prostate cancer in the Apa-RP study. July 8, 2024

Coffee, PI3K signaling pathway, and prostate cancer: a prospective study in the Health Professionals Follow-up Study. July 8, 2024

Prostate-Specific Antigen Values in Transgender Women Receiving Estrogen. July 7, 2024

Diet and Tumor Genetics Conspire to Promote Prostate Cancer Metabolism and Shape the Tumor Microenvironment. July 7, 2024

Comparison of oncological outcomes of upfront androgen receptor signaling inhibitors and combined androgen blockade in Japanese patients with metastatic castration-sensitive prostate cancer. July 5, 2024

Seminal Papers in Urology: Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. July 5, 2024

Focal Therapy in Grade Group 3 Prostate Cancer. July 5, 2024

Association of Genomic Prostate Score at positive margin with recurrence after radical prostatectomy. July 5, 2024

Prostate cancer risk assessment and avoidance of prostate biopsies using fully automatic deep learning in prostate MRI: comparison to PI-RADS and integration with clinical data in nomograms. July 5, 2024

A prostate cancer gastrointestinal transcriptional phenotype may be associated with diminished response to AR-targeted therapy. July 5, 2024

A prospective evaluation of the prostate microbiome in malignant and benign tissue using transperineal biopsy. July 5, 2024

FOXA2 rewires AP-1 for transcriptional reprogramming and lineage plasticity in prostate cancer. July 5, 2024

Is There a Place for De-escalating Therapy in Patients with Metastatic Hormone-sensitive Prostate Cancer? July 4, 2024

Targeted Investigational Treatment Analysis of Novel Anti-androgen (TITAN) study: ultralow prostate-specific antigen decline with apalutamide plus androgen-deprivation therapy. July 4, 2024

Clinical Impact of Contouring Variability for Prostate Cancer Tumor Boost. July 4, 2024

Page 33 of 1436